[Stock in Focus] Rokit Healthcare Emerges as a 'Game-Changer' in the $249 Billion Kidney Disease Treatment Market... Revitalizing Damaged Kidney Tissue

Rokit Healthcare is experiencing a strong performance. Expectations surrounding its omentum-based treatment platform, which fundamentally induces tissue regeneration by promoting angiogenesis in damaged kidney tissue and inhibiting fibrosis, appear to be influencing the company's stock price. The company explained that, through a mechanism that suppresses inflammatory responses while simultaneously improving blood flow, it is proposing a new treatment paradigm for areas such as chronic kidney disease and acute kidney injury, which have been difficult to address with existing therapies.

Chronic kidney disease affects approximately 800 million people worldwide, and the market for its treatment continues to grow. As of 2024, the chronic kidney disease treatment market is estimated to be worth about $85.4 billion, and it is projected to reach approximately $120.7 billion by 2030. The end-stage renal disease (ESRD) market is expected to grow from $84.2 billion in 2024 to $249 billion by 2035.

As of 10:22 a.m. on June 10, 2025, Rokit Healthcare was trading at 17,260 won, up 2,960 won (20.70%) from the previous trading day.

Rokit Healthcare announced that it presented its kidney regeneration platform at the 61st European Renal Association (ERA 2025), the world's most prestigious nephrology conference, which was held in Austria from June 4 to June 7, and that its technological capabilities were recognized in the global medical market.

A company representative stated, "The ERA presentation was a meaningful occasion to share the scientific validity and clinical applicability of our technology with the global academic community," adding, "It is attracting attention as a breakthrough that can delay the initiation of dialysis for patients with renal failure, who previously had no alternatives other than organ transplantation or dialysis."

Currently, research is underway as part of a government-funded regenerative medicine technology development project in collaboration with Asan Medical Center in Seoul and Boramae Medical Center, Seoul National University College of Medicine, with pilot clinical trials scheduled to begin within this year. In addition, the company is simultaneously developing personalized treatment strategies by integrating AI-based prognosis and prediction technologies for end-stage renal disease (ESRD).

Rokit Healthcare has already secured a technological advantage over competitors based on domestic patents. Building on this, the company is preparing to develop AI-based disease prediction models for additional organs in the future.

Yoo Seokhwan, CEO of Rokit Healthcare, stated, "A structural approach to regenerating kidney function has long been considered one of the most difficult challenges, but our technology offers a viable solution," adding, "As a treatment technology that can delay the need for dialysis, it will become a game-changer that significantly improves patients' quality of life."

He added, "Based on the achievements of national multidisciplinary research projects and global academic presentations, we will accelerate the commercialization of our technology and plan to make a full-scale market entry starting with the pilot clinical trial at Asan Medical Center in Seoul, scheduled for the second half of the year."

Last year, at the Asia-Pacific Congress of Nephrology (APCN), the company received the Outstanding Poster Award for its 'decellularization and recellularization-based kidney regeneration technology,' thereby demonstrating the research achievements and completeness of its technology on an international level.